Modulating ACSL4 activity or interfering with metabolic crosstalk, such as PCK2 and P4HA1 pathways, may restore ferroptotic sensitivity in resistant NPC phenotypes. This evidence concerns the gene PCK2 and nasopharyngeal carcinoma.